Dr. Pradeep Uchil is an Associate Professor in the Department of Microbial Pathogenesis at Yale School of Medicine. He earned his PhD in Molecular Virology from the Indian Institute of Science (Bangalore, India) and completed postdoctoral training at Yale University under Prof. Walther Mothes, focusing on Retrovirus Cell Biology and Innate Immunity. Research Focus: Viral replication, spread, and host interactions using mouse models Expertise: Innate immunity, viral immunology, multi-scale imaging techniques Techniques: Noninvasive whole-body bioluminescence imaging (BLI) His work systematically characterizes key tissues and cell types involved in viral pathogenesis through imaging. Collaborative efforts include frequent co-authors like Walther Mothes, Priti Kumar, and Craig Wilen. Publications span flavivirus structure, retroviral transmission, and immune checkpoint mechanisms.
Carlos Martin is a Full Professor of Microbiology at the Faculty of Medicine, University of Zaragoza, Spain (since 2005). Previously, he served as Assistant Professor at the same institution (1992-2005), Research Assistant at the Pasteur Institute Paris (1989-1992), and held postdoctoral fellowships at the Pasteur Institute (1987-1988) and Fundación Marqués de Valdecilla (1986). He has over 30 years of expertise in mycobacterial genetics and molecular epidemiology of tuberculosis, leading the development of novel TB vaccines like MTBVAC. MD and PhD in Medicine Specializes in tuberculosis vaccine mechanisms, bacterial genetics, and pathogenicity Led collaborative TB research projects across Europe, Africa, and America His work focuses on improving tuberculosis vaccines through molecular genetic approaches, studying virulence factors, and antibiotic resistance mechanisms in Mycobacterium tuberculosis. His research has been continuously funded by Spanish Ministry of Health and European Union programs since 1992. Recent publications highlight his breakthroughs in aerosol TB vaccine delivery (2021), lineage-specific vaccine potential (2020), and demonstrating MTBVAC's non-specific immune effects (2020). His team's work has led to first-in-human trials of live-attenuated TB vaccines (2015) and discovery of key virulence regulators like phoP (2001). Scientific Awards & Honors: 2017 Elected Member of Royal Academy of Medicine of Zaragoza 2010 Research Prize from Gobierno de Aragón 2006 Prize from Fundación Ecología y Desarrollo 1987 EMBO Short-Term Postdoctoral Fellowship Contributor to Spain's National Plan Against TB (2007) His research group, affiliated with CIBERES (respiratory disease network) and Tuberculosis Vaccine Initiative (TBVI), has secured continuous funding since 1992 from national and EU programs. He has published 189+ articles with over 10,000 citations and an h-index of 45.
Dr. Colin Chu is a clinical academic ophthalmologist and Wellcome Trust Clinical Research Career Development Fellow at the UCL Institute of Ophthalmology. He holds affiliations with Moorfields Eye Hospital as an Honorary Consultant Ophthalmologist. His academic journey includes a PhD from UCL, medical training at the University of Oxford, and undergraduate studies at the University of Cambridge. He has held roles such as NIHR Academic Clinical Lecturer at the University of Bristol and Fulbright Scholar at the NIH, contributing to advanced imaging techniques and immunology research. Education: PhD: University College London (2011–2014) MB BCh: University of Oxford MA: University of Cambridge Research Interests: Uveitis, ocular immunology, in vivo immune cell imaging, gene therapy, spatial biology, and multiplexed tissue imaging (e.g., IBEX). Grants/Awards: Wellcome Trust Clinical Research Career Development Fellowship Fulbright Scholarship MRC Clinical Research Training Fellowship Funding from Moorfields Eye Charity and NIHR His lab focuses on advancing diagnostic and therapeutic approaches for ocular diseases, including metagenomic sequencing for uveitis, immune responses to gene therapy vectors, and imaging innovations like adaptive optics and IBEX. Collaborations span institutions like NIH, University of Rochester, and Great Ormond Street Hospital. Key projects include the BIRD-SET study on Birdshot Chorioretinopathy and clinical trials for glaucoma gene therapy. His work bridges clinical practice and research, with a focus on improving patient outcomes through novel imaging and molecular techniques.
Dr. Angela Fonceca is an Adjunct Research Fellow in the School of Biomedical Sciences at the University of Western Australia, affiliated with the Microbiology and Immunology department. Her research focuses on respiratory viral infections, particularly Respiratory Syncytial Virus (RSV), and their interactions with host immune systems. She leads projects investigating biofilm disruption therapies, viral persistence mechanisms, and phage therapy applications in cystic fibrosis. Her research interests span airway immunology, infectious disease dynamics, and translational therapies targeting respiratory pathogens. Key areas include RSV persistence in dendritic cells, viral-host interactions, and biofilm-related respiratory infections. Dr. Fonceca has authored over 12 peer-reviewed publications, with notable contributions on RSV transmission in daycare settings and pre-clinical models for biofilm-induced diseases. She has secured funding for 6 research grants, including investigations into RSV transmission dynamics and commercial development of biofilm disruptors. Her work contributes to UN Sustainable Development Goals related to good health and well-being.
Prof. Petronela Ancuta is a Full Professor at the Université de Montréal's Faculty of Medicine, Department of Microbiology, Infectious Diseases, and Immunology. She leads research on HIV pathogenesis, focusing on immune mechanisms and viral persistence. Her work integrates immunology and virology to identify therapeutic targets for HIV cure strategies. Key roles: Principal Investigator in CANCURE (Canadian HIV Cure Enterprise), CRCHUM member, and leader in HIV reservoir studies. Education: PhD in Immunology from Université Paris XI and postdoctoral training at Harvard Medical School. She teaches immunology courses and supervises numerous PhD and Master's students. Research focuses on Th17 cells, myeloid cells, circadian rhythms, and HIV's impact on cardiovascular health. Her grants include IRSC-funded projects on viral reservoirs and immune modulation. Collaborations span Canadian and international institutions. Notable projects include exploring RORC2 as a therapeutic target, circadian clock effects on HIV, and IL-32's role in inflammation. Her lab's findings aim to translate into clinical interventions for HIV remission.
Dr. Thomas Murray is a Professor of Pediatrics (Infectious Disease) at Yale University School of Medicine, affiliated with the Department of Pediatrics and Yale Institute for Global Health. He serves as Associate Chair for Quality & Safety in Pediatrics and Associate Medical Director for Infection Prevention at Yale New Haven Children's Hospital, alongside leading the Winchester Pediatric Tuberculosis Clinic. With a dual MD/PhD from the University of Connecticut, he completed his pediatric residency and fellowships in infectious diseases and medical microbiology at Yale. Education: MD and PhD, University of Connecticut (2000) Pediatric Residency, Yale-New Haven Hospital (2003) Fellowships: Pediatric Infectious Diseases & Medical Microbiology, Yale University School of Medicine (2007-2008) Research Interests: Dr. Murray focuses on infection prevention in cystic fibrosis (CF) patients, studying host-pathogen interactions (e.g., Pseudomonas aeruginosa) and novel disinfection methods for home respiratory equipment. His work explores anti-inflammatory therapies like Sanguinate to mitigate CF lung inflammation and investigates aerosolized bacteriophage treatments for drug-resistant pathogens. He also examines broader infection control strategies, including hand dryer hygiene and antibiotic stewardship during outbreaks like COVID-19. Key Contributions: Recent studies highlight his work on monocyte adaptation in inflamed lungs, barriers to NICU infection prevention, and gender disparities in pediatric sepsis treatment. His research bridges clinical care and translational science, with funding from the Cystic Fibrosis Foundation. Awards: Champion of Children Award (2022) Norman J Siegel Faculty Award (2021) Grants & Labs: Supported by the Cystic Fibrosis Foundation, Dr. Murray collaborates with teams at the Center for Immersive Technologies and Winchester Tuberculosis Program. His lab investigates CF pathogenesis, disinfection efficacy, and pediatric infection dynamics.
Professor Paul Dyson is a molecular microbiologist at Swansea University's Swansea University Medical School within the Faculty of Medicine, Health and Life Sciences. He leads a research group focused on exploiting bacteria for medical and biotechnological applications, including antibiotic production, RNA interference in insects, and tumor-targeting bacteria. He holds a BSc from the University of East Anglia, a PhD from the University of Glasgow, and a DSc from Swansea University. His research has yielded four patents involving antibiotic-producing bacteria, RNAi in insect vectors, and bacterial cancer therapy. Teaching interests include Genetics and Biochemistry modules, such as Animal Development and Molecular Microbiology. He actively supervises undergraduate and postgraduate research projects. Recent work spans bacterial cancer therapy models, symbiont-mediated RNAi in insects, and exploring microbial defense systems for new antimicrobials. Collaborations include studies on vector insects' immune responses and paratransgenesis strategies.
Dr Sian-eleri Owens is a Lecturer in Biomedical Sciences at Swansea University Medical School, with a focus on Blood Sciences and Immunohaematology. Fluent in Welsh and English, she teaches courses such as cell biology and laboratory skills. Her research investigates enhancing innate defenses against pathogens, particularly mechanisms involving pore-forming toxins and cellular protection. She holds a BSc from the University of Wales Institute Cardiff and a PhD from Cardiff University School of Pharmacy and Pharmaceutical Sciences. Education: BSc (Hons) in Biomedical Science, University of Wales Institute Cardiff; PhD in Myosin Light Chain-Dependent Modulation of Tight Junctions, Cardiff University School of Pharmacy. Research Interests: Cell biology, pathogen tolerance, and innate immune responses. Her work explores glucocorticoids, oxysterols, and bisphosphonates as protective agents against pore-forming toxins from bacteria. Collaborations include the National Botanic Garden of Wales for bilingual science outreach. Publications: Over 20 peer-reviewed articles in journals such as Communications Biology, Frontiers in Immunology, and The FASEB Journal, focusing on cellular protection mechanisms and antimicrobial defense strategies. Supervision: Currently advising a PhD student on cholesterol-dependent cytolysin protection mechanisms, co-supervised with Dr James Cronin. Labs/Teams: Affiliated with the Institute of Life Science at Swansea University, contributing to interdisciplinary research in biomedical defense mechanisms.
Paola Massari is a Research Associate Professor at Tufts University School of Medicine in the Department of Immunology. She leads research focused on preclinical vaccine development targeting bacterial pathogens like Neisseria gonorrhoeae and Chlamydia trachomatis , with expertise in innate and adaptive immunity, bacterial pathogenesis, and host responses. Ph.D. in Advanced Biotechnology (Protein Engineering, 1995) from University of Napoli Federico II Laurea (BS/MSc, 1990) from University of Naples Her research leverages transcriptomics and structural biology to identify vaccine antigens, with recent work on gonococcal copper storage proteins and chlamydial MOMP-based vaccines. She has secured multiple NIH grants for projects including gonococcal hypothetical protein vaccines and Fur regulon analysis. Key awards: NIH grants (2022-2026, 2021-2023), Vaxcyte collaborations Professional roles: Editorial Board member for Vaccines , Frontiers in Immunotherapies , and Open Journal of Apoptosis Teaching: Delivered 'Laboratory Techniques' course at Tufts (2025)
Jose A. Domingos is an academic researcher affiliated with James Cook University (JCU), focusing on aquaculture, fish genetics, and aquatic animal health. He completed his PhD at JCU in 2014, with a thesis on selective breeding programs for barramundi. His research spans genetic parameters in fish species like Malabar red snapper and cobia, transcriptome analysis of gonadal development, and disease management in farmed fish. He has contributed to understanding environmental impacts on aquaculture through studies on temperature effects, dietary contaminants, and viral infections. Domingos collaborates extensively with international teams on genomic resources, molecular diagnostics, and computational tools for fish farming. His work integrates genetics, epigenetics, and environmental science to address challenges in sustainable aquaculture. Research interests include genetic selection strategies, disease surveillance via environmental DNA (eDNA), and the application of molecular tools to improve fish health and productivity. He has published over 38 peer-reviewed articles in journals such as Aquaculture , Frontiers in Genetics , and Journal of Fish Diseases . His studies often emphasize practical applications for commercial fish farming, including optimizing growth traits, controlling pathogens, and developing diagnostic assays. While no specific grants or lab affiliations are detailed in the provided texts, his collaborative projects suggest involvement in JCU’s marine and tropical biology research groups. Domingos’ work bridges fundamental biology with applied aquaculture solutions, contributing to both academic knowledge and industry practices.
Dr. Alexander V. Georgiev is a Senior Lecturer in Primatology and College Director of Postgraduate Research Studies at Bangor University's School of Environmental and Natural Sciences (College of Science & Engineering). He holds a PhD in Human Evolutionary Biology from Harvard University (2012) and a BSc in Biology from Sofia University (2005). His research focuses on primate reproductive ecology, physiology, and conservation, particularly through the Zanzibar Red Colobus Project, which examines the impacts of habitat disturbance on endangered primates. Teaching responsibilities include modules such as Introduction to Primatology , Primatology Field Course , and Dissertation in Biological Sciences . He supervises postgraduate research on primate behavioral ecology and conservation. His research highlights include studies on primate gut microbiome evolution, human-primate interactions, and the physiological costs of reproduction in primates. Recent grants include a £34,990 project (2023–2024) assessing bidirectional risks of human-primate interactions in Zanzibar. Key findings include the discovery of novel truffle species consumed by bonobos and insights into CD4 receptor diversity’s role in primate lentivirus resistance. His work bridges behavioral ecology with conservation policy, addressing threats like vehicle collisions to endangered species.
Anna Arnqvist Björklund is a Professor of Biomedicine and Associate Dean for Research at the Faculty of Medicine, Umeå University. She leads research in the Department of Medical Biochemistry and Biophysics, focusing on bacterial pathogenesis mechanisms, particularly Helicobacter pylori adherence and extracellular vesicle functions. Her work bridges microbiology, cell biology, and clinical pathology. Her research explores how H. pylori exploits pH-responsive adhesins (BabA/SabA) and extracellular vesicles to colonize gastric mucosa and evade host defenses. Key areas include molecular regulation of adhesion proteins, protease-mediated tissue damage, and virulence factor interactions with host cells. Publications highlight her work on vesicle-mediated pathogen adaptation, pH-dependent gene regulation, and cell junction disruption mechanisms. Collaborations span structural biology, animal models, and NMR-based lipid analysis. Her articles reveal a focus on translational microbiology, linking molecular mechanisms to clinical outcomes like gastric cancer and peptic ulcers. While no explicit awards are listed, her extensive publication record indicates impactful contributions to infectious disease research. Education background includes PhD-level training in microbiology, with research history at Umeå University and international collaborations. She advises on academic quality systems for medical and technical programs at the university.
Charles Armitage is a research-active academic specializing in immunology and infectious diseases, with a primary focus on Chlamydia infections and their impact on reproductive and neurological health. He earned his PhD from Queensland University of Technology in 2012 and has since been a prolific contributor to the field, publishing extensively in high-impact journals. His research is centered on host immune responses, immunopathology, and mechanisms of infertility and neuroinvasion associated with chlamydial infections. His research interests include mucosal immunology, host-pathogen interactions in Chlamydia , vaccine development, and the role of immune cells such as CD8+ T cells, NKT cells, and macrophages in disease progression. He has extensively studied the dissemination of Chlamydia muridarum in mouse models and its effects on male and female reproductive tracts, including sperm DNA damage and oviduct pathology. The most recent publications (2021–2024) highlight a strong trend toward understanding neuroinvasion by Chlamydia pneumoniae and its potential link to Alzheimer's disease, as well as the role of IgG and IL-17A in exacerbating genital immunopathology. His work frequently employs mouse models and translational approaches to bridge basic science with clinical implications. Scientific Awards: No specific awards mentioned in the provided text. Dr. Armitage has collaborated extensively with Kenneth W. Beagley and other researchers across immunology, microbiology, and reproductive medicine. He has contributed to studies involving grant-funded research on chlamydial pathogenesis, vaccine development, and diagnostic methods, although specific grant details are not listed. His work has appeared in major journals such as Scandinavian Journal of Immunology , Biology of Reproduction , and Scientific Reports . He is embedded in a collaborative research environment, likely within a dedicated immunology or infectious disease research group, focusing on both basic mechanisms and translational outcomes of chlamydial infections. His continued publication record suggests active involvement in mentoring students and junior researchers, though no direct advisees are named.
Bryan Briney, PhD is an Associate Professor in the Department of Immunology and Microbiology at Scripps Research. He leads a research program focused on multi-omics analyses of the human humoral immune response to infectious diseases such as HIV, Lassa virus, Ebola, and SARS-CoV-2. His work integrates computational immunology, antibody engineering, and systems biology approaches to advance vaccine design and therapeutic development. Dr. Briney earned his PhD in Microbiology & Immunology from Vanderbilt University (2012) and a BS in Biochemistry and Cell Biology from UC San Diego (2007). Before joining Scripps Research as faculty in 2012 as a Postdoctoral Fellow, he transitioned to Assistant Professor (2012-2022) and currently holds the rank of Associate Professor since 2022. His research interests span HIV vaccine development, antibody repertoire analysis, and computational methods for antibody discovery. Key areas include identifying broadly neutralizing antibodies (bNAbs), understanding B cell lineage maturation pathways, and creating novel vaccine candidates targeting conserved viral epitopes. His lab has pioneered techniques like antigen barcoding and antibody language models to accelerate discovery processes. Notable recent work includes identifying ultra-broad coronavirus neutralizing antibodies, developing Lassa virus vaccine candidates using structural ensembles, and demonstrating HIV gp41-targeting bNAb precursors through vaccination. His team also investigates pre-pandemic SARS-CoV-2 immunity patterns and antibody responses in pediatric elite-neutralizers. Dr. Briney has received significant recognition including awards from the Baxter Family Foundation and Bill & Melinda Gates Foundation. His lab maintains active collaborations in computational immunology and has contributed to high-impact platforms like the Clonify repertoire analysis tool.
John Teijaro, PhD is a Professor in the Department of Immunology and Microbiology at The Scripps Research Institute. His research focuses on persistent viral infections (LCMV) and acute influenza pathogenesis, with emphasis on type 1 interferon's role in immunity and cytokine-driven pathology. He holds a B.S. in Molecular & Cell Biology (Millersville University, 2004) and a Ph.D. in Microbiology & Immunology (University of Maryland, 2009). Research interests include viral immunology, innate immune responses, cytokine amplification mechanisms, and tissue-resident memory T cells. His work has demonstrated that endothelial cells drive cytokine storms during influenza and that blocking IFN-I signaling enhances LCMV clearance via CD4 T cell activation. Notable awards include the 2014 Baxter Foundation Faculty Scholar award and multiple travel/abstract awards. His recent studies explore SARS-CoV-2 antivirals, therapeutic antibodies, and immunomodulatory drug candidates targeting JAK/STAT pathways and glycan checkpoints. Key collaborations include work on SLC15A4 inhibitors (Nature Chemical Biology 2024), CD28-sialic acid interactions (ACS Central Science 2021), and STING pathway modulation (Science 2020). Current projects aim to dissect pulmonary immune cell networks and develop novel therapies for viral infections and cancer.
